Coya Therapeutics, Inc. (COYA) — SEC Filings
Coya Therapeutics, Inc. (COYA) — 35 SEC filings. Latest: 4 (Apr 9, 2026). Includes 18 8-K, 5 10-Q, 4 SC 13G/A.
View Coya Therapeutics, Inc. on SEC EDGAR
Overview
Coya Therapeutics, Inc. (COYA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 4 filed on Apr 9, 2026: On April 9, 2026, Coya Therapeutics, Inc. filed a Form 4, indicating changes in beneficial ownership of securities. The filing details transactions related to the company's stock, with specific changes to be detailed within the document.
Sentiment Summary
Across 35 filings, the sentiment breakdown is: 1 bearish, 34 neutral. The dominant filing sentiment for Coya Therapeutics, Inc. is neutral.
Filing Type Overview
Coya Therapeutics, Inc. (COYA) has filed 1 3, 1 4, 18 8-K, 5 10-Q, 2 DEF 14A, 1 10-K/A, 2 10-K, 4 SC 13G/A, 1 DEFA14A with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (35)
Risk Profile
Risk Assessment: Of COYA's 28 recent filings, 1 were flagged as high-risk, 16 as medium-risk, and 11 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $3,985,754 |
| Net Income | -$15,517,565 |
| EPS | -$0.93 |
| Debt-to-Equity | 0.17 |
| Cash Position | $28,129,866 |
| Operating Margin | -82.8% |
| Total Assets | $32,042,878 |
| Total Debt | $4,758,387 |
Key Executives
- Pavao Mark H
- 0001297988
- Fred Grossman
- David Snyder
- Howard Berman
- Dr. Arun Swaminathan
- Dr. Michael J. Ybarra
- Dr. Jonathan M. Roth
- Dr. David J. Ebersole
- Dr. Amir Mohammadi
- Dr. Michael J. McVicar
- Anabella Villalobos, Ph.D.
- Dov Goldstein, M.D., M.B.
Industry Context
Coya Therapeutics operates in the highly competitive and capital-intensive biotechnology sector, focusing on developing novel therapeutics. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory hurdles. Success often depends on scientific innovation, successful clinical trials, and securing substantial funding to navigate these challenges.
Top Tags
disclosure (5) · 10-Q (4) · material-agreement (3) · equity-sale (3) · 8-K (3) · corporate-governance (3) · pharmaceuticals (3) · insider-filing (2) · Biotechnology (2) · 8-k (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $15.5M | Increased from $11.9M in prior year, indicating widening losses. |
| Cash and Cash Equivalents | $28.1M | Decreased from $38.3M, highlighting significant cash burn. |
| Accumulated Deficit | $56.3M | Reflects ongoing losses since inception. |
| Research and Development Expenses | $11.8M | Increased from $9.9M, showing higher investment in pipeline. |
| Collaboration Revenue | $3.98M | Increased from $3.55M, providing some offset to expenses. |
| Common Stock Outstanding | 20,924,456 | As of November 10, 2025, indicating potential dilution. |
| Commission File Number | 001-41583 | Identifies the company's SEC filing history |
| Annual Meeting Date | 20250626 | Shareholders will vote on company matters on this date. |
| Fiscal Year End | 2024-12-31 | The proxy statement covers the company's performance up to this date. |
| Reporting Period End Date | 2025-03-31 | Indicates the latest financial snapshot provided. |
| Prior Year Quarter End | 2024-03-31 | Provides a comparative point for financial performance. |
| Start of Q1 2024 | 2024-01-01 | Marks the beginning of the period for which expenses are detailed. |
| SEC File Number | 001-41583 | Identifies Coya Therapeutics, Inc. in SEC filings. |
| Filing Date | 2024-11-06 | The date the 10-Q was officially submitted to the SEC. |
| Period End Date | 2024-03-31 | 10-Q filing period |
Frequently Asked Questions
What are the latest SEC filings for Coya Therapeutics, Inc. (COYA)?
Coya Therapeutics, Inc. has 35 recent SEC filings from Jan 2024 to Apr 2026, including 18 8-K, 5 10-Q, 4 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of COYA filings?
Across 35 filings, the sentiment breakdown is: 1 bearish, 34 neutral. The dominant sentiment is neutral.
Where can I find Coya Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Coya Therapeutics, Inc. (COYA) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Coya Therapeutics, Inc.?
Key financial highlights from Coya Therapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for COYA?
The investment thesis for COYA includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Coya Therapeutics, Inc.?
Key executives identified across Coya Therapeutics, Inc.'s filings include Pavao Mark H, 0001297988, Fred Grossman, David Snyder, Howard Berman and 8 others.
What are the main risk factors for Coya Therapeutics, Inc. stock?
Of COYA's 28 assessed filings, 1 were flagged high-risk, 16 medium-risk, and 11 low-risk.
What are recent predictions and forward guidance from Coya Therapeutics, Inc.?
Forward guidance and predictions for Coya Therapeutics, Inc. are extracted from SEC filings as they are enriched.